Registry for patients undergoing transcatheter mitral or tricuspid valve therapy
The Prospecive OBSERVational Munich Interventional MITRAl-Valve Registry
Deutsches Herzzentrum Muenchen · NCT04577248
This study collects information from patients who have had transcatheter mitral or tricuspid valve therapy to see how well these treatments work over time.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 5000 (estimated) |
| Ages | 18 Years to 110 Years |
| Sex | All |
| Sponsor | Deutsches Herzzentrum Muenchen (other) |
| Locations | 1 site (Munich, Bavaria) |
| Trial ID | NCT04577248 on ClinicalTrials.gov |
What this trial studies
This observational registry collects data on patients treated with transcatheter mitral or tricuspid valve therapy at the Deutsches Herzzentrum München. It aims to assess long-term mortality outcomes following these interventions. The study includes all consecutive patients who meet the eligibility criteria and provides insights into the effectiveness of edge-to-edge valve repair techniques. Data will be gathered to enhance understanding of patient outcomes in this specific treatment context.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 with mitral or tricuspid valve conditions who are deemed suitable for transcatheter therapy by a heart team.
Not a fit: Patients unable to cooperate with the study protocol or those not eligible for transcatheter valve therapy will not benefit from this registry.
Why it matters
Potential benefit: If successful, this registry could improve patient care by identifying factors that influence long-term outcomes after valve therapy.
How similar studies have performed: Similar observational registries have shown success in improving understanding of valve therapies, making this approach a valuable addition to existing knowledge.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age above 18 years and consentable * Mitral Valve Regurgitation, Mitral Valve Stenosis, Tricuspid Valve Regurgitation, Tricuspid Stenosis * Transcatheter mitral or tricuspid valve therapy considered best option by heart-team decision * Written informed consent Exclusion Criteria: * Patient's inability to fully cooperate with the protocol
Where this trial is running
Munich, Bavaria
- Deutsches Herzzentrum München des Freistaates Bayern, Technische Universität München — Munich, Bavaria, Germany (RECRUITING)
Study contacts
- Principal investigator: Tobias Rheude, MD — Dept. of Cardiology, Deutsches Herzzentrum München
- Study coordinator: Patrick Mayr, MD
- Email: mayrp@dhm.mhn.de
- Phone: +498912180
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Mitral Valve Regurgitation, Mitral Valve Stenosis, Tricuspid Valve Regurgitation